Ali Roghanian, PhD, has several years of academic and industry experience of working with experimental models of disease to develop novel therapeutics. He completed a PhD in immunology at the University of Edinburgh, followed by postdoctoral work at the University of Cambridge, and working as a Senior Study Manager at Envigo (Huntingdon Life Sciences). In 2012, while working as a Senior Research Fellow at the University of Southampton, he successfully led a project in collaboration with BioInvent on generating and characterizing novel human FcγRIIB antibodies for treating lymphoma and leukemia patients (currently in Phase I/IIa clinical trials). In 2015, he received a personal fellowship to work as Visiting Scientist at the Koch Institute for Integrative Cancer Research at MIT, USA, where he generated novel humanized mouse models of cancer. Ali was appointed as an Assistant Professor in cancer immunology and immunotherapy in 2018, at the Centre for Cancer Immunology at Southampton.